Janssen is providing refunds for 340B overcharges on four drugs during Q3 and Q4 2019.

Drugmakers Janssen and Kala Providing Refunds for 340B Overcharges

Janssen Pharmaceuticals is giving 340B entities refunds for overcharges on 14 NDCs during the third and fourth quarters of 2019, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.

“The revisions were due to standard restatements of Medicaid pricing data,” the company’s notice said.  Janssen is owned by pharmaceutical giant Johnson & Johnson.

Janssen’s refunds are on its antipsychotics Invega and Risperdal, blood thinner Xarelto, and Duragesic fentanyl patch. Kala’s is on its Inveltys eye drops for inflammation and pain after eye surgery.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report